What is the clinical evidence from this study?

Study design: Cohort. Population: Hypertension and cognitive impairment (n=1573). Intervention: Cognitive impairment (MMSE 25). Primary outcome: Noncompliance with antihypertensive therapy (compliance ratio <= 0.50) (OR 2.0, 95% CI 1.4 to 2.8).

What does this research mean for the field?

Cognitive impairment in elderly patients is associated with a twofold increased risk of noncompliance with antihypertensive therapy, particularly among those living alone. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To examine the association between cognitive impairment and noncompliance with antihypertensive drug therapy in elderly individuals.

December 1, 2001Clinical Pharmacology & Therapeutics

Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study

Q: What are the key findings of this study?

Cognitive impairment in elderly patients was associated with a twofold increased risk of noncompliance with antihypertensive therapy (OR 2.0; 95% CI 1.4-2.8), especially in those living alone.

Q: What does this research mean for the field?

Cognitive impairment in elderly patients is associated with a twofold increased risk of noncompliance with antihypertensive therapy, particularly among those living alone. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To examine the association between cognitive impairment and noncompliance with antihypertensive drug therapy in elderly individuals.

View Full Paper

Ask AI

Bookmark

Key result

Cognitive impairment in elderly patients was associated with a twofold increased risk of noncompliance with antihypertensive therapy (OR 2.0; 95% CI 1.4-2.8), especially in those living alone.

Why the study?

Does cognitive impairment increase the risk of noncompliance with antihypertensive drugs in elderly patients?

Population

1573 elderly patients without dementia at baseline who received 3 or more consecutive antihypertensive…

Comparison

Cognitive impairment vs Normal cognitive function

Design

Cohort

Follow-up

average 1609 days

Authors

MSMaría Marqueta de Salas

Discussion

Member takes

Overview

May warrant adherence monitoring in cognitively impaired elderly living alone; leaves open effects of cognitive interventions on compliance.

Key Points

To examine the association between cognitive impairment and noncompliance with antihypertensive drug therapy in elderly individuals.
Analyzed data from the Rotterdam Study, a prospective community-based cohort study, evaluating 1979 participants aged ≥55 years without dementia at baseline who had received ≥3 consecutive antihypertensive prescriptions across ≥6 months.
Assessed cognitive performance via two consecutive Mini Mental State Examination (MMSE) scores between 1991 and 1996, defining impairment as scores ≤25 on both visits versus scores >25.
Quantified compliance by dividing days with medication coverage by total follow-up days, categorizing noncompliance as a ratio ≤0.50 and compliance as ≥0.80.
Among 1573 participants followed for an average of 1609 days (mean age 68 years), cognitive impairment doubled the risk of noncompliance (adjusted relative risk, 2.0; 95% CI, 1.4 to 2.8).
Stratification by living arrangement demonstrated that the elevated risk of noncompliance was concentrated among cognitively impaired individuals living alone (OR, 2.9; 95% CI, 1.2 to 7.5).

Study Design

Type

Cohort (n=1,573)

Structured PICO

Does cognitive impairment increase the risk of noncompliance with antihypertensive drugs in elderly patients?

Population

1573 elderly patients (mean age 68 years) without dementia at baseline who received 3 or more consecutive antihypertensive prescriptions for at least 6 months

Intervention

Cognitive impairment (MMSE scores <= 25 on two consecutive assessments)

Comparator

Normal cognitive function (MMSE scores > 25 on both occasions)

Outcome

Noncompliance with antihypertensive drugs (compliance ratio <= 0.50)

Main Result

Effect estimate: OR 2.0 (95% CI 1.4 to 2.8)

Cognitive impairment is an independent predictor of noncompliance with antihypertensive medications in elderly patients, particularly those living alone.

Cite This Study

María Marqueta de Salas (2001) conducted a cohort in Hypertension and cognitive impairment (n=1,573). Cognitive impairment (MMSE <= 25) vs. Normal cognitive function (MMSE > 25) was evaluated on Noncompliance with antihypertensive therapy (compliance ratio <= 0.50) (OR 2.0, 95% CI 1.4 to 2.8). Cognitive impairment in elderly patients was associated with a twofold increased risk of noncompliance with antihypertensive therapy (OR 2.0; 95% CI 1.4-2.8), especially in those living alone.

synapsesocial.com/papers/6a189d3a70dbaace42cf7db1 https://doi.org/10.1067/mcp.2001.119812

View Full Paper

Ask AI

Bookmark

December 1, 2001Clinical Pharmacology & Therapeutics

Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study

View Full Paper

Ask AI

Bookmark

Key result

Cognitive impairment in elderly patients was associated with a twofold increased risk of noncompliance with antihypertensive therapy (OR 2.0; 95% CI 1.4-2.8), especially in those living alone.

Why the study?

Does cognitive impairment increase the risk of noncompliance with antihypertensive drugs in elderly patients?

Population

1573 elderly patients without dementia at baseline who received 3 or more consecutive antihypertensive…

Comparison

Cognitive impairment vs Normal cognitive function

Design

Cohort

Follow-up

average 1609 days

Authors

MSMaría Marqueta de Salas

Discussion

Member takes

Overview

May warrant adherence monitoring in cognitively impaired elderly living alone; leaves open effects of cognitive interventions on compliance.

Key Points

To examine the association between cognitive impairment and noncompliance with antihypertensive drug therapy in elderly individuals.
Analyzed data from the Rotterdam Study, a prospective community-based cohort study, evaluating 1979 participants aged ≥55 years without dementia at baseline who had received ≥3 consecutive antihypertensive prescriptions across ≥6 months.
Assessed cognitive performance via two consecutive Mini Mental State Examination (MMSE) scores between 1991 and 1996, defining impairment as scores ≤25 on both visits versus scores >25.
Quantified compliance by dividing days with medication coverage by total follow-up days, categorizing noncompliance as a ratio ≤0.50 and compliance as ≥0.80.
Among 1573 participants followed for an average of 1609 days (mean age 68 years), cognitive impairment doubled the risk of noncompliance (adjusted relative risk, 2.0; 95% CI, 1.4 to 2.8).
Stratification by living arrangement demonstrated that the elevated risk of noncompliance was concentrated among cognitively impaired individuals living alone (OR, 2.9; 95% CI, 1.2 to 7.5).

Study Design

Type

Cohort (n=1,573)

Structured PICO

Does cognitive impairment increase the risk of noncompliance with antihypertensive drugs in elderly patients?

Population

1573 elderly patients (mean age 68 years) without dementia at baseline who received 3 or more consecutive antihypertensive prescriptions for at least 6 months

Intervention

Cognitive impairment (MMSE scores <= 25 on two consecutive assessments)

Comparator

Normal cognitive function (MMSE scores > 25 on both occasions)

Outcome

Noncompliance with antihypertensive drugs (compliance ratio <= 0.50)

Main Result

Effect estimate: OR 2.0 (95% CI 1.4 to 2.8)

Cognitive impairment is an independent predictor of noncompliance with antihypertensive medications in elderly patients, particularly those living alone.

Cite This Study

synapsesocial.com/papers/6a189d3a70dbaace42cf7db1 https://doi.org/10.1067/mcp.2001.119812

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark